Page last updated: 2024-09-05

erlotinib hydrochloride and Basal Cell Cancer

erlotinib hydrochloride has been researched along with Basal Cell Cancer in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Choi, JS; Choi, YL; Jung, K; Kim, YJ; Kundu, J; Kwon, MJ; Lee, SE; Oh, E; Seo, J; Shin, YK; Song, JY	1
Balanis, NG; Carlin, CR; Pascuzzi, PE; Schiemann, BJ; Schiemann, WP; Wendt, MK; Williams, WK	1

Other Studies

2 other study(ies) available for erlotinib hydrochloride and Basal Cell Cancer

Article	Year
MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. International journal of cancer, 2014, May-15, Volume: 134, Issue:10 Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Indoles; Kaplan-Meier Estimate; Middle Aged; Molecular Targeted Therapy; Neoplasms, Basal Cell; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sulfones; Triple Negative Breast Neoplasms	2014
The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6. Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplasm Metastasis; Neoplasms, Basal Cell; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Tumor Suppressor Proteins	2015

Article

Year

MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.

International journal of cancer, 2014, May-15, Volume: 134, Issue:10

Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Indoles; Kaplan-Meier Estimate; Middle Aged; Molecular Targeted Therapy; Neoplasms, Basal Cell; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sulfones; Triple Negative Breast Neoplasms

2014

The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.

Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:1

Topics: Adaptor Proteins, Signal Transducing; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplasm Metastasis; Neoplasms, Basal Cell; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Tumor Suppressor Proteins

2015